Today was the second and final day of the OxFora 14th Intellectual Property and Competition Forum, entitled “The Global Chess Game: International Patent Strategy in a Fragmented World”. The event, which took place at the DPMA Forum in Munich (as well as online) kicked off with a heated debate between speakers from Nokia, Qualcomm, Amazon, and Dell, on preliminary injunctions and rate-setting kicks yesterday (
June 23, 2026
ip fray
article
).
Context
: In February 2026, Nokia, Warner Bros. Discovery, and Paramount agreed to resolve their global dispute over video streaming technologies through a UK court-determined reasonable and non-discriminatory (RAND) license, replacing parallel litigation with a single rate-setting process in England (
February 26, 2026
ip fray
article
Context:
In October 2023 Pictiva Displays International Ltd sued Samsung Electronics for patent infringement in the United States District Court for the Eastern District of Texas. A jury awarded Pictiva a total of $191.4 million in damages in November 2025, finding the asserted claims of two of its patents infringed and not invalid.
In May 2024, Samsung Display, a subsidiary of Samsung Electronics, filed petitions for inter partes review (IPR) of the same two patents with the U.S. Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (PTAB). The PTAB denied institution of one IPR but granted the other, issuing a final written decision in February 2026 finding all challenged claims unpatentable – including one claim found infringed and not invalid by the Eastern District of Texas jury.
To Read The Full Story
Sign In
Context:
Enanta Pharmaceuticals, Inc. sued Pfizer Inc. on June 21, 2022 in the U.S. District Court for the District of Massachusetts, just one week after the patent issued, alleging that Pfizer’s COVID-19 antiviral Paxlovid infringed Enanta’s
U.S. Patent No. 11,358,953
(“Functionalized peptides as antiviral agents”), which is directed to compounds and methods for inhibiting coronavirus replication. Enanta sought damages and ongoing royalties rather than an injunction, asserting at the time that it did not intend to impede Paxlovid’s production or sale (
June 21, 2022, Enanta Pharmaceuticals, press release